The PCNA-associated protein PARI negatively regulates homologous recombination via the inhibition of DNA repair synthesis

Investor logo
Investor logo

Warning

This publication doesn't include Faculty of Arts. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

BURKOVICS Peter DOME Lili JUHASZ Szilvia ALTMANNOVÁ Veronika ŠEBESTA Marek PAČESA Martin FUGGER Kasper SORENSEN Claus Storgaard LEE Marietta Y.W.T. HARACSKA Lajos KREJČÍ Lumír

Year of publication 2016
Type Article in Periodical
Magazine / Source Nucleic Acids Research
MU Faculty or unit

Faculty of Medicine

Citation
Doi http://dx.doi.org/10.1093/nar/gkw024
Field Genetics and molecular biology
Keywords CELL NUCLEAR ANTIGEN; UBIQUITIN-BINDING DOMAINS; DAMAGE TOLERANCE PATHWAY; BLOOMS-SYNDROME HELICASE; SACCHAROMYCES-CEREVISIAE; REPLICATION FORK; POSTREPLICATION REPAIR; TRANSLESION SYNTHESIS; GENOMIC STABILITY; SUMO MODIFICATION
Description Successful and accurate completion of the replication of damage-containing DNA requires mainly recombination and RAD18-dependent DNA damage tolerance pathways. RAD18 governs at least two distinct mechanisms: translesion synthesis (TLS) and template switching (TS)-dependent pathways. Whereas TS is mainly error-free, TLS can work in an error-prone manner and, as such, the regulation of these pathways requires tight control to prevent DNA errors and potentially oncogenic transformation and tumorigenesis. In humans, the PCNA-associated recombination inhibitor (PARI) protein has recently been shown to inhibit homologous recombination (HR) events. Here, we describe a biochemical mechanism in which PARI functions as an HR regulator after replication fork stalling and during double-strand break repair. In our reconstituted biochemical system, we show that PARI inhibits DNA repair synthesis during recombination events in a PCNA interaction-dependent way but independently of its UvrD-like helicase domain. In accordance, we demonstrate that PARI inhibits HR in vivo, and its knockdown suppresses the UV sensitivity of RAD18-depleted cells. Our data reveal a novel human regulatory mechanism that limits the extent of HR and represents a new potential target for anticancer therapy.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.